UnknownNot Applicable

Thyroid Hormones Treatment in Asthma Exacerbation

Israel100 participantsStarted 2014-07

Plain-language summary

This study will explore whether supplementation with thyroid hormones in the set-up of asthma exacerbation could improve the clinical outcomes. The study will include adults admitted to Rambam health care campus for moderate to severe Asthma exacerbation. The study is a prospective, randomized, double-blind, placebo-controlled, clinical trial. Patients will be randomized on admission to receive treatment with intra-venous thyroxine (100mcg once on admission and additional 100mcg after 12 hours) or placebo. The study treatment will be given only after the initial bronchodilator therapy, oxygen and informed consent are given. The primary endpoint is the time to return of the peak expiratory flow (PEF) rate to normal values or personal base line.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years of age or older * Known Asthma * The exacerbation is defined as moderate or severe. * Not currently enrolled as an active participant in another clinical trial of a medical therapy or device. * The patient or first degree family relative (in cases where the patient is intubated) has authorized his/her consent to participate in this trial. The patient will be asked to give his consent only after initial bronchodilator therapy Exclusion Criteria: * 60 years of age or older * Known thyroid disorders * Subject where thyrotoxicosis is suspected * Known heart disease * Heart rate \> 140

What they're measuring

time to normalization of PEF (peak expiratory flow)

Timeframe: one week

Trial details

NCT IDNCT02086799

SponsorRambam Health Care Campus

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-07

Contact for this trial

gidon berger, MD

972 502061166 g_berger@rambam.health.gov.il